2 résultats
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Auteurs / Authors
Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, Hiret S, Dixmier A, Renault PA, Becht C, Raffy O, Dayen C, Mazieres J, Pichon E, Langlais A, Morin F, Moro-Sibilot D, Besse B
Journal / Conference
European Journal of Cancer
Année / Year
2020
PMID / session
Etude IFCT
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE
Auteurs / Authors
Alexis B. Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlesi, Gerard Zalcman, Patrick Dumont, Damien Pouessel, Claire Poulet, Pierre Jean Souquet, Sandrine Hiret, Adrien Dixmier, Patrick-Aldo Renault, Alexandra Langlais, Marie Paule Lebitasy, Franck Morin, Denis Moro-Sibilot, Benjamin Besse
Journal / Conference
ASCO
Année / Year
2016
PMID / session
Etude IFCT